News
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...
A bunch of men have been talking about 'Ozempic penis' as a side-effect of the drug, but an expert has explained the truth ...
1h
InvestorsHub on MSNNovo Nordisk Shares Edge Higher After Seeking EU Approval for Higher-Dose WegovyShares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.
Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...
Kate Farms has launched high-protein plant-based shakes to tackle "critical nutrition gaps" from GLP-1 use, its first product ...
2h
Investor's Business Daily on MSNRevived WeightWatchers Rallies, In 'Strongest Position In Years'Analyst initiates coverage of WeightWatchers with a buy rating after bankruptcy reemergence. IPO hot streak continues.
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...
Researchers say GLP-1 medicines might be able to help with migraines.
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...
Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...
A MUM-OF-TWO who shed almost half her bodyweight using fat jabs has shared the one piece of advice she wish she knew before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results